share_log
Breakings ·  Oct 30, 2023 09:32

Junshi Biotech's A shares opened 13% higher, Junshi Biotech's H shares opened 14.5% higher, and the PD-1 monoclonal antibody was approved for listing by the US FDA.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment